Projects per year
Personal profile
Biography
Dr Paul Yeh is a consultant haematologist and clinician-scientist with dual appointments at Monash Health and Monash University. He is the Head of the Blood Cancer Biomarkers Laboratory in the School of Clinical Sciences at Monash Health. His laboratory’s research interest is in the use of blood based molecular biomarkers to understand normal and malignant haematopoiesis. The aim of the research is to translate novel biomarker discoveries from the bench into clinical practice to improve outcomes in patients with haematological malignancies.
Dr Yeh has been the finalist of the Victorian Premier’s Awards for Health and Medical Research (Clinical Researcher) and a recipient of the EHA/ASH translational research in Haematology (TRTH) scholar award. He is currently a recipient of a NHMRC/MRFF Emerging Leadership Fellow Grant.
His clinical interest is in molecular haematology and myeloid neoplasms where he is a consultant haematopathologist in the molecular pathology department and the clinical lead for myeloproliferative neoplasms at Monash Health.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Medicine, PhD, Molecular monitoring and screening in haematological malignancies, University of Melbourne
Award Date: 7 Nov 2018
Bachelor of Medicine, Bachelor of Surgery, MBBS, University of Melbourne
Award Date: 3 Dec 2005
Bachelor of Medical Science, BMedSci
Award Date: 3 Dec 2005
Research area keywords
- Haematology
- haematological malignancies
- clonal haematopoiesis
- Myeloid leukaemia
- Myeloproliferative Diseases
- Genomics & Transcriptomics
- Next Generation Sequencing
- circulating tumour DNA
- Whole genome sequencing
- bioinformatics
- Multi-omics
- Biomarkers
- Lymphoid Malignancies
-
Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis
Yeh, P. (Primary Chief Investigator (PCI))
15/10/25 → 14/10/30
Project: Research
-
A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study
Yeh, P. (Primary Chief Investigator (PCI))
23/05/25 → 22/05/30
Project: Research
-
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK- 3543) versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants
Yeh, P. (Primary Chief Investigator (PCI))
9/12/24 → 8/12/29
Project: Research
-
A Phase 3, Randomised, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Yeh, P. (Primary Chief Investigator (PCI))
27/11/24 → 26/11/29
Project: Research
-
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and/or in Combination with Azacitidine in Adults with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome/AML (MDS/AML) or Myelodysplastic Syndrome with Excess Blasts (MDS-EB)
Yeh, P. (Primary Chief Investigator (PCI))
29/07/24 → 28/07/29
Project: Research
Research output
- 19 Article
-
Next-generation sequencing RNA fusion panel for the diagnosis of haematological malignancies
Ngo, T. Q., Goh, A. F. N., Dorwal, P., Leong, E., Shortt, J., Fedele, P. L., Gilbertson, M., Fong, C. Y., Shanmuganathan, N., Kumar, B. & Yeh, P., Apr 2025, In: Pathology. 57, 3, p. 340-347 8 p.Research output: Contribution to journal › Article › Research › peer-review
3 Citations (Scopus) -
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach
Tedjaseputra, A., Tey, A., Nalpantidis, A., Grigoriadis, G., Fleming, S., Vilcassim, S., Fedele, P. L., Low, M. S. Y., Yeh, P., Gilbertson, M., Bennett, A., Gregory, G. P., Oh, D., Gairns, D., Kaplan, Z., Chunilal, S. D., Brown, S., Opat, S., Chua, C. C. & Shortt, J., May 2025, In: Internal Medicine Journal. 55, 5, p. 749-759 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Smart Nonuniformity for Calibrating Sequencing Depth of a Targeted Gene Panel to Simultaneously Detect Somatic and Germline Variants
O'Reilly, R. L., Harraka, P., Burke, J., Belluoccio, D., Yeh, P., Howlett, K., Behrouzfar, K., Rewse, A., Tsimiklis, H., Giles, G. G., Hopper, J. L., Bubb, K. J., Nicholls, S. J., Milne, R. L. & Southey, M. C., Aug 2025, In: The Journal of Molecular Diagnostics. 27, 8, p. 705-712 8 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Day-21 bone marrow findings incorrectly designate residual leukaemia in FLT3-mutated acute myeloid leukaemia treated with intensive induction plus midostaurin: a morphology-focused study
Tedjaseputra, A., Roy, S., Htun, K., Oh, D., McQuilten, Z., Yeh, P., Bennett, A., Yuan Low, M. S., Chunilal, S., Wood, E. M. & Shortt, J., 2024, In: Pathology. 56, 4, p. 548–555 8 p.Research output: Contribution to journal › Article › Research › peer-review
-
Saliva-derived DNA is suitable for the detection of clonal haematopoiesis of indeterminate potential
O’Reilly, R. L., Burke, J., Harraka, P., Yeh, P., Howlett, K., Behrouzfar, K., Rewse, A., Tsimiklis, H., Giles, G. G., Bubb, K. J., Nicholls, S. J., Milne, R. L. & Southey, M. C., Dec 2024, In: Scientific Reports. 14, 1, 8 p., 18917.Research output: Contribution to journal › Article › Research › peer-review
Open Access4 Citations (Scopus)
Prizes
-
EHA/ASH translational research in Haematology program (TRTH) scholar
Yeh, P. (Recipient), 2018
Prize: National/international honour
-
-
-
-